For people diagnosed with lung cancer, receiving a second opinion can be an important step in confirming treatment decisions or opting for a new approach to treatment. In Mary Burlie’s case, getting a second opinion changed everything. Although her [...]
Ellen S. is a three-year survivor of stage 4 (IV) non-small cell lung cancer. She retired two years ago after a 22-year career as an occupational therapist in New York. She loves to travel and hike and has visited [...]
On October 16, 2023, the U.S. Food and Drug Administration (FDA) approved a new treatment plan for people receiving Keytruda (pembrolizumab) for resectable non-small cell lung cancer (NSCLC). This approval is based on results from the KEYNOTE-671 (NCT03425643) clinical [...]
By Tamara Gabrielli, MD Dr. Gabrielli recently retired after a 30-year career as an anesthesiologist in Maryland and Washington, D.C. She lives in Rockville, MD and has three daughters in their 20s. She just celebrated her 64th birthday. [...]
GO2 for Lung Cancer's Phone Buddy program began in the early 1990s. Thanks to the many volunteers who give their time to speak with others about their own lung cancer experience, it is still going strong today. The program [...]
On January 26, 2023, the U.S. Food and Drug Administration (FDA) approved Keytruda (pembrolizumab) for adjuvant (additional) treatment following surgery and chemotherapy for stage IB, II, or IIIA non-small cell lung cancer (NSCLC). This approval was based on the [...]
Question: My tumor’s original biopsy showed that I had non-small cell lung cancer with an EGFR biomarker. Recently, the cancer started progressing and my most recent biopsy shows that I have transformed small cell lung cancer. What does this [...]
On December 12th, 2022, the Food and Drug Administration (FDA) approved Krazati (adagrasib) for treatment of non-small cell lung cancer (nsclc) where there is a KRAS G12C mutation. This approval is for patients who have received at least one line [...]
On November 10th, 2022, the Food and Drug Administration (FDA) approved Imjudo (tremelimumab) in combination with Imfinzi (durvalumab) and platinum-based chemotherapy for treatment of non-small cell lung cancer where there are no changes in ALK or EGFR. The FDA [...]
Author: Daniel A. Saez, MSc, Manager, LungMATCH Navigation Program For many years, the treatment options given to patients diagnosed with early stage non-small cell lung cancer (NSCLC) was limited to surgery with or without chemotherapy to improve outcomes. However, [...]